Home Neuronal Signaling Serotonin Transporter inhibitor - 5-HT Receptor inhibitor Escitalopram Oxalate

research use only

Escitalopram Oxalate Serotonin Transporter inhibitor

Cat.No.S4064

Escitalopram Oxalate is a selective serotonin (5-HT) reuptake inhibitor (SSRI) with Ki of 0.89 nM.
Escitalopram Oxalate Serotonin Transporter inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 414.43

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 414.43 Formula

C20H21FN2O.C2H2O4

 Storage (From the date of receipt)
CAS No. 219861-08-2 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.C(=O)(C(=O)O)O

Solubility

In vitro
Batch:

DMSO : 83 mg/mL (200.27 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 25 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
5-HT [2]
0.89 nM(Ki)
In vitro
Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.[1] In vitro studies show that escitalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram is found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase. [2]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05730062 Not yet recruiting
Opioid Induced Respiratory Depression|Depressive Disorder|Anxiety Disorders
Leiden University Medical Center
 March 15 2023 Phase 1
NCT05210140 Unknown status
Depressive Disorder Major
University of Belgrade|Clinical Centre of Serbia|Institute of Mental Health Serbia|Military Medical Academy Belgrade Serbia
 July 16 2020 --
NCT04239339 Completed
Healthy
Rigshospitalet Denmark|University of Cambridge|Lundbeck Foundation
 April 28 2020 Phase 4
NCT03912974 Completed
Healthy
University Hospital Basel Switzerland
 July 4 2019 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.